At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 72 enrolled
Drug / intervention
Niagendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-controlled Parallel Group Clinical Trial of Nicotinamide Riboside to Evaluate NAD+ Levels in Individuals With Persistent Cognitive and Physical Symptoms After COVID-19 Illness ("Long-COVID")
In Brief
A Phase 4 clinical trial evaluating Niagen for Covid19 and 2 related conditions. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers"). 60% of participants will receive Niagen and 40% will receive PBO. Outcomes will consist of standardized cognitive, neuropsychiatric, physical, functional and biomarker assessments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Sequelae of; Infection, Cognitive Symptom
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartAug 2021
Primary CompletionOct 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedMar 22, 2021
Enrollment StartAug 28, 2021
Primary CompletionOct 5, 2023
Study CompletionFeb 23, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.3 years ago
Interventions
Niagendrug
The intervention consists of taking Niagen and completing all tasks divided into 6 visits.